P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

HyQvia (IGHy) is a recombinant human hyaluronidase (rHuPH20)-facilitated subcutaneous immunoglobulin (SCIG) 10% replacement therapy for adults with primary immunodeficiency diseases (PIDD). To acquire long-term safety data on IGHy, and assess prescribed treatment regimens and administration in routine clinical practice, a global post-authorization safety study was initiated in the United States in November 2015.

http://ift.tt/2iFPZLe